Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076342 · ClinicalTrials.gov registry record · Phase 4
The Role of mGluR5 in CBT-I
A Phase 4 study of Major Depressive Disorder (MDD), sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT07076342 is a Phase 4 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 42 participants, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07076342, a Phase 4 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy for Insomnia
- DRUG PET Scan with [11C]ABP688
Study Locations (1)
New York
- Stony Brook University: Dept of Psychiatry - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076342
The ClinicalTrials.gov registry entry for NCT07076342 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (73% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Behavioral Therapy for Insomnia is the first listed.
NCT07076342 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07076342 about?
NCT07076342 is a clinical study titled "The Role of mGluR5 in CBT-I". This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
What is the current status of trial NCT07076342?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2025-08-01. Estimated completion is 2030-03-31.
What conditions does trial NCT07076342 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT07076342?
The interventions under investigation include: Cognitive Behavioral Therapy for Insomnia (BEHAVIORAL), PET Scan with [11C]ABP688 (DRUG).
Who is sponsoring clinical trial NCT07076342?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076342 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
RECRUITING · Phase 4
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
Neurofeedback to Treat Depression - 2
RECRUITING · NA
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.